Pre-made Garetosmab benchmark antibody ( Whole mAb, anti-INHBA/ACT therapeutic antibody, Anti-EDF/FRP Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Garetosmab biosimilar, Whole mAb, Anti-INHBA/ACT Antibody: Anti-EDF/FRP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Garetosmab is a VelocImmune-derived fully-human monoclonal antibody that binds and neutralizes Activin A, which is involved in the development of heterotopic bone in people with FOP. Garetosmab is currently being studied in adults with FOP.
| Products Name (INN Index) | Pre-Made Garetosmab biosimilar, Whole mAb, Anti-INHBA/ACT Antibody: Anti-EDF/FRP therapeutic antibody |
|---|---|
| INN Name | Garetosmab |
| Target | INHBA |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Regeneron Pharmaceuticals |
| Conditions Approved | NA |
| Conditions Active | Fibrodysplasia ossificans progressiva,Osteroporosis |
| Conditions Discontinued | Musculoskeletal disorders |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | INHBA |
| Package |
